The Therapy of Vulvar Carcinoma—Evaluation of Surgical Options in a Retrospective Monocentric Study [PDF]
Life, 2023 (1) Background: Surgical-oncological treatment methods are continuously put to the test in times of evidence-based medicine—notably, a constant reevaluation remains key, especially for tumor entities with increasing incidence such as vulvar carcinoma. (2)
Peter Jankowski +7 more
doaj +2 more sources
Recurrent herpes simplex virus mimicking vulvar carcinoma in patient with Human Immunodeficiency Virus: A case report [PDF]
Gynecologic Oncology Reports, 2023 Patients with human immunodeficiency virus (HIV) are at increased risk for developing other gynecologic conditions, including herpes simplex virus (HSV) and vulvar intraepithelial neoplasia (VIN)/carcinoma.
Rachel McKean +4 more
doaj +2 more sources
WNL we never looked: vulvar carcinoma incidence after screening cutoff [PDF]
International Journal of Women's DermatologyThe incidence of vulvar carcinoma increases with age, though elderly women receive less aggressive cancer therapies and fewer strategies aimed at cancer prevention.
Amaris N. Geisler, MD, Jodi E. Ganz, MD
doaj +2 more sources
Circulating Hsa-miR-431-5p as Potential Biomarker for Squamous Cell Vulvar Carcinoma and Its Premalignant Lesions [PDF]
Diagnostics, 2021 Vulvar squamous cell carcinoma (VSCC) develops from high-grade squamous intraepithelial lesions (HSIL) and differentiated vulvar intraepithelial neoplasia (dVIN).
Mateusz Bujko +8 more
doaj +2 more sources
HPV16 viral characteristics in primary, recurrent and metastatic vulvar carcinoma [PDF]
Papillomavirus Research, 2018 Vulvar carcinoma is the fourth most common gynecological malignancy. Two separate carcinogenic pathways are suggested, where one is associated with the human papillomavirus (HPV) and HPV16 the most common genotype.The aim of this study was to evaluate ...
Gabriella Lillsunde Larsson +4 more
doaj +2 more sources
Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines [PDF]
Gynecologic Oncology Reports, 2022 There are limited treatment options for patients with advanced vulvar cancer. However, several immune checkpoint inhibitors (ICIs) are FDA-approved or NCCN-Compendia–listed for qualified patients with advanced disease.
Aaron Praiss +5 more
doaj +2 more sources
Time trends in human papillomavirus prevalence and genotype distribution in vulvar carcinoma in Norway [PDF]
Acta Obstetricia et Gynecologica ScandinavicaIntroduction Approximately 25%–43% of all vulvar carcinomas are associated with human papillomavirus (HPV). In many countries, vulvar carcinoma incidence rates are increasing, possibly due to greater HPV exposure.
Christin Julia Meltzer‐Gunnes +6 more
doaj +2 more sources
Recurrence of vulvar carcinoma: A multidisciplinary approach. [PDF]
Gynecol Oncol Rep, 2019 Although oncogynaecological management of bulky vulvar tumors tends to minimally-invasive approaches preceded by neoadjuvant therapies, ultra-radical surgery with curative intent may still have an important role. These procedures remain associated with significant short and long-term complications, imposing the need for novel reconstructive techniques [
Rei M +5 more
europepmc +6 more sources
Vulvar carcinoma: dilemma, debates, and decisions. [PDF]
Cancer Manag Res, 2018 Vulvar carcinoma is a rare and aggressive gynecological malignancy. It affects elderly females, with the mean age at diagnosis being 55-60 years. Regional metastasis to inguinal lymph nodes is common. There is a high incidence of pelvic node involvement, especially in those with pathologically positive inguinal nodes.
Mitra S +7 more
europepmc +7 more sources
Indian Journal of Pathology and Microbiology, 2012 Although the basal cell carcinoma (BCC) is the most common malignancy of skin, it is rarely seen in vulva and constitutes 2% to 4% of all vulvar cancers. The cause is unknown but, chronic vulvar irritation is the most important underlying factor.
Mustafa Kara +2 more
doaj +3 more sources